Literature DB >> 27329903

Nasal bi-level positive airway pressure (BiPAP) versus nasal continuous positive airway pressure (CPAP) in preterm infants ≤32 weeks: A retrospective cohort study.

Zhi-Hui Rong1, Wen-Bin Li1, Wei Liu1, Bao-Huan Cai1, Jing Wang1, Min Yang1, Wei Li1, Li-Wen Chang1.   

Abstract

AIM: To investigate whether Bi-level positive airway pressure (BiPAP), compared with nasal continuous positive airway pressure (CPAP), is a more effective therapeutic strategy in preterm infants ≤32 weeks.
METHODS: All inborn infants between 26(+1) and 32(+6) weeks' gestation, admitted to the neonatal intensive care unit (NICU ) of Tongji Medical Hospital between 1 January, 2010 and 31 December, 2011 (the 2010-2011 cohort or CPAP cohort) and between 1 January, 2012 and 31 December, 2013 (the 2012-2013 cohort or BiPAP cohort), were retrospectively identified. The primary outcome was intubation in infants < 72 h of age; secondary outcomes were mortality and the incidence of bronchopulmonary dysplasia (BPD).
RESULTS: There were 213 in the 2010-2011 cohort and 243 infants in the 2012-2013 cohort. There were fewer infants intubated within the first 72 h of age in the 2012-2013 cohort than in the 2010-2011 cohort (15% vs. 23%, P < 0.05). Of the infants who received some form of positive airway pressure, 12/94 (13%) of infants on BiPAP versus 23/74 (31%) on CPAP were subsequently intubated (P < 0.01). There was no difference in the incidence of moderate and severe BPD between the two groups (7% vs. 8%, P=0.52).
CONCLUSIONS: In this retrospective cohort study, we found BiPAP, compared with CPAP, reduced the need for intubation within the first 72 h of age.
© 2016 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).

Entities:  

Keywords:  bi-level nasal positive airway pressure; bronchopulmonary dysplasia (BPD); nasal continuous positive airway pressure; preterm infants

Mesh:

Year:  2016        PMID: 27329903     DOI: 10.1111/jpc.13175

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  7 in total

Review 1.  Sleep Abnormalities in Multiple Sclerosis.

Authors:  Giorgos K Sakkas; Christoforos D Giannaki; Christina Karatzaferi; Mauro Manconi
Journal:  Curr Treat Options Neurol       Date:  2019-01-31       Impact factor: 3.598

Review 2.  Current insights in non-invasive ventilation for the treatment of neonatal respiratory disease.

Authors:  Dhivya Lakshmi Permall; Asfia Banu Pasha; Xiao-Qing Chen
Journal:  Ital J Pediatr       Date:  2019-08-19       Impact factor: 2.638

Review 3.  Non-invasive Ventilation for Children With Chronic Lung Disease.

Authors:  Emine Atag; Uros Krivec; Refika Ersu
Journal:  Front Pediatr       Date:  2020-11-11       Impact factor: 3.418

4.  Non-invasive duo positive airway pressure ventilation versus nasal continuous positive airway pressure in preterm infants with respiratory distress syndrome: a randomized controlled trial.

Authors:  Arash Malakian; Mohammad Reza Aramesh; Mina Agahin; Masoud Dehdashtian
Journal:  BMC Pediatr       Date:  2021-07-06       Impact factor: 2.125

5.  Heated Humidified High Flow Nasal Cannula (HHHFNC) is not an effective method for initial treatment of Respiratory Distress Syndrome (RDS) versus nasal intermittent mandatory ventilation (NIMV) and nasal continuous positive airway pressure (NCPAP).

Authors:  Amir-Mohammad Armanian; Ramin Iranpour; Mehdi Parvaneh; Nima Salehimehr; Awat Feizi; Mostafa Hajirezaei
Journal:  J Res Med Sci       Date:  2019-08-28       Impact factor: 1.852

6.  Risk factors for BiPAP failure as an initial management approach in moderate to late preterm infants with respiratory distress.

Authors:  Heekwon Son; Eui Kyung Choi; Kyu Hee Park; Jeong Hee Shin; Byung Min Choi
Journal:  Clin Exp Pediatr       Date:  2020-02-15

Review 7.  Practical aspects on the use of non-invasive respiratory support in preterm infants.

Authors:  Nehad Nasef; Hend Me Rashed; Hany Aly
Journal:  Int J Pediatr Adolesc Med       Date:  2020-02-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.